Navigation Links
Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc
Date:5/10/2013

PARSIPPANY, N.J., May 10, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a global specialty pharmaceutical leader, today confirmed that Actavis has entered into early stage discussions with Warner Chilcott plc (Nasdaq: WCRX) regarding a potential combination of the two companies.  Actavis further stated that no agreement has been reached and it does not intend to issue further comment regarding its business development initiatives. 

About Actavis, Inc.Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.  The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. 

For press release and other company information, visit Actavis' Web site at http://www.actavis.com.

Forward-Looking Statement Statements contained in this press release that refer to Actavis' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Actavis' strategic initiatives, including a potential transaction with Warner Chilcott plc, are forward-looking statements. It is important to note that Actavis' goals and expectations are not predictions of actual performance. Actavis' performance, at times, will differ from its goals and expectations. Actual results may differ materially from Actavis' current expectations depending upon a number of factors affecting Actavis' business. These factors include, among others, the inherent uncertainty associated with pending strategic transactions; the difficulty of predicting the timing and outcome of business and corporate development efforts and activities and risks that such activities may not result in a transaction being consummated; the ability to recognize the anticipated synergies and benefits of any transaction; and such other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis' Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the period March 31, 2013. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements. CONTACTS: Investors:Lisa DeFrancesco (862) 261-7152Media:Charlie Mayr(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20130124/NY47381LOGO )


'/>"/>
SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
2. Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion
3. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
4. Actavis, Inc. to Host First Quarter 2013 Earnings Conference Call and Webcast
5. Former Clinton Deputy Solicitor General sheds light on flaws in Federal Trade Commissions case in FTC v. Actavis Inc.
6. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
7. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
8. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
9. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
10. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
11. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
Breaking Medicine News(10 mins):